CCD-Blocking-SolutionA convenient feature in the
CCD-Blocking-SolutionA convenient feature in the
AlleisaScreen® system
Many allergens are glycoproteins, which consist of a protein part and one or more glycan chains. Glycan chains are composed of different sugars linked together and are bound via an amino-group (N-glycan) or a hydroxyl-group (O-glycan) to the protein part. N-glycans are particularly immunogenic and can induce the production of IgE, specific for N-glycans, which are usually pathologically irrelevant.
These IgE antibodies are highly cross-reactive for glycoproteins of plants, insects and molluscs. Therefore, glycan chains are named “cross-reactive carbohydrate determinants” (CCDs). CCDs have been found in allergen extracts of plant origin like tree, weed and grass pollen, vegetables, fruits, seeds, nuts and latex but also in insect venoms, snails and parasites
More than 20% of all allergic patients produce anti-CCD IgE antibodies. The sensitisation of patients against CCDs probably results from contact with pollen or from insect stings. While usually the occurrence of CCDs in allergen extracts induce no positive results in skin tests, they can lead to positive results or enhanced positive results in in vitro test systems without any pathologically relevance. For these reasons the possible occurrence of CCD-specific IgE antibodies must be considered if in vitro test systems are used.
Profit by the advantages of the CCD-Blocking-Solution:
Improvement of the specificity of the allergy diagnostic according to the recommendations of the German Society for Allergology and Clinical Immunology (Deutsche Gesellschaft für Allergologie und klinische Immunologie)
Inhibition of glycan-specific IgE antibodies - Only peptide-specific IgE antibodies are detected
Just a short preincubation step of 30 Min before running the test
No change in the required serum amount of 300 µl in the AlleisaScreen® test procedure – the serum is mixed with 10% of the CCD-Blocking- Solution. This serum-CCD-mix can be directly used in the test
Further test procedure for the AlleisaScreen® stays unaffected
